AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~strikethrough~~ and additions are underlined.

1. (Currently amended) A compound represented by the following ~~general~~ formula (I), the pharmaceutically acceptable salt or the isomer thereof:



(I)

wherein

X is an oxygen or sulfur atom;

A is an aminomethylene or methylene group;

B is a 4-*tert*-butylbenzyl, a 3,4-dimethylphenylpropyl, an oleyl or 

(I-1) group wherein m is integer of 0 or 1 and n is 1 or 2;

R_1 is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfone or a lower alkylcarbonyl group having 1 to 5 carbon atoms;

R_2 is a hydrogen atom, a methoxy group or halogen atom;

R_3 is a hydrogen atom, a methoxy group or halogen atom;

R_4 is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R_5 is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R_6 is a lower alkyl group having 1 to 5 carbon atoms or a phenyl group.

2. (Currently amended) The compound according to claim 1 represented by the following ~~general~~ formula (III), the pharmaceutically acceptable salt or the isomer thereof:



(III)

wherein

X is an oxygen atom or a sulfur atom;

R_1 is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfone or a lower alkylcarbonyl group having 1 to 5 carbon atoms;

R_2 is a hydrogen atom, a methoxyl group or a halogen atom;

R_3 is a hydrogen atom or a halogen atom;

B is  ,  or  group.

3. (Original) The compound according to claim 2 wherein said compound is at least one selected from the group consisting of;

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[3-methoxy-4-(methylsulfonylamino) benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl] thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[3-chloro-4-(methylsulfonylamino)benzyl] thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)-3-nitrobenzyl] thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[2-fluoro-4-(methylsulfonylamino)benzyl] thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[2-chloro-4-(methylsulfonylamino)benzyl] thiourea,

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[4-(methylsulfonyl amino)benzyl] thiourea,

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[3-methoxy-4-(methylsulfonylamino)benzyl] thiourea,

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl] thiourea,

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[2-fluoro-4-(methylsulfonylamino)benzyl] thiourea,

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[2-chloro-4-(methylsulfonylamino)benzyl] thiourea,

N-[2-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[4-(methylsulfonyl amino)benzyl] thiourea, and

N-[2-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl] thiourea.

4. (Currently amended) The compound according to claim 1 represented by the following ~~general~~ formula (IV), the pharmaceutically acceptable salt or the isomer thereof:



(IV)

wherein

R_1 is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfone or a lower alkylcarbonyl group having 1 to 5 carbon atoms;

R_2 is a hydrogen atom, a methoxyl group or a halogen atom;

R_3 is a hydrogen atom or a halogen atom;

B is  , 

or 

group.

5. (Original) The compound according to claim 4 wherein said compound is N-(4-*tert*-butylbenzyl)-N-hydroxy-[4-(methylsulfonylamino)phenyl] acetamide.

6. (Currently amended) A compound represented by ~~general~~ formula (II), the pharmaceutically acceptable salt or the isomer thereof:



(II)

wherein

X is an oxygen or sulfur atom;

B' is B or a secondary amine substituted with B,

wherein B is a 4-*tert*-butylbenzyl, a 3,4-dimethylphenylpropyl, an oleyl or



(II-1) group, wherein m is integer of 0 or 1 and n is 1 or 2;

R_1 is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfonyl group or lower alkylcarbonyl group having 1 to 5 carbon atoms;

R_2 is a hydrogen atom, a methoxy group or halogen atom;

R_3 is a hydrogen atom, a methoxy group or halogen atom;

R_4 is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R_5 is a hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms;

R_6 is a lower alkyl group having 1 to 5 carbon atoms or a phenyl group.

7. (Currently amended) The compound according to claim 6 represented by ~~general~~ formula (V), the pharmaceutically acceptable salt or the isomer thereof:



(V)

wherein

X is an oxygen atom or a sulfur atom;

R_1 is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfonyl group or lower alkylcarbonyl group having 1 to 5 carbon atoms;

R_2 is a hydrogen atom or a halogen atom;

R_3 is a hydrogen atom;

B is  ,  or  group.

8. (Currently amended) The compound according to claim 7 wherein said compound is at least one selected from the group consisting of;

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]thiourea,

N-[2-(3,4-dimethylbenzyl)-3(pivaloyloxy)propyl]-N-hydroxy-N-[4-(methylsulfonyl amino)benzyl]thiourea,

N-(4-*tert*-butylbenzyl)-N-hydroxy-N-[4-(methylsulfonylamino)benzyl]urea, and

N-[2-(3,4-dimethylbenzyl)-3(pivaloyloxy)propyl]-N-hydroxy-N-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea.

9. (Currently amended) The compound according to claim 6 represented by ~~general~~ formula (VI), the pharmaceutically acceptable salt or the isomer thereof:



(VI)

wherein

R_1 is a halogen-substituted or unsubstituted lower alkylsulfone having 1 to 5 carbon atoms, arylsulfonyl group or lower alkylcarbonyl group having 1 to 5 carbon atoms;

R_2 is a hydrogen atom, a methoxyl group or a halogen atom;

R_3 is a hydrogen atom, a methoxyl group or a halogen atom;

B is  ,  or  group.

10. (Original) The compound according to claim 9 wherein said compound is N-hydroxy-N-[4-(methylsulfonylamino)benzyl]-2-(4-*tert*-butylphenyl)acetamide.

11. (Currently amended) A pharmaceutical composition comprising the compound of ~~general~~ formula (I) as set forth in claim 1 as an active ingredient in amount effective amount for an antagonist of vanilloid receptor together with pharmaceutically acceptable carriers or diluents.

12. (Currently amended) A pharmaceutical composition comprising the compound of ~~general~~ formula (I) as set forth in claim 1 as an active ingredient in amount effective to alleviate or treat pain diseases or inflammatory diseases together with pharmaceutically acceptable carriers, excipients or diluents.

13. (Currently amended) A pharmaceutical composition comprising an efficient amount of the compound represented by ~~general~~ formula (II) as set forth in claim 6 as an active ingredient in amount effective for an antagonist of vanilloid receptor together with pharmaceutically acceptable carriers or diluents.

14. (Currently amended) A pharmaceutical composition comprising the compound of ~~general~~ formula (II) as set forth in claim 6 as an active ingredient in amount effective amount to alleviate or treat pain disease together with pharmaceutically acceptable carriers or diluents.

15. (Currently amended) The pharmaceutical composition according to claim 12 or 14 wherein said pain disease is at least one selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, ~~a respiratory disorder such as~~ asthma, ~~or~~ chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence,

stomach-duodenal ulcer, inflammatory bowel disease caused by the vanilloid receptor antagonistic activity.

16. (Original) A pharmaceutical composition comprising the compound of any one of claims 1 to 10 as an active ingredient in amount effective for analgesic and anti-inflammation together with pharmaceutically acceptable carriers or diluents.

17. (Currently amended) A pharmaceutical composition comprising the compound of any one of claims 1 to 10 as an active ingredient together with pharmaceutically acceptable carriers or diluents for ~~preventing and~~ treating urgent urinary incontinence.

18. (Canceled)

19. (New) A method of treating pain disease and inflammatory disease by showing vanilloid receptor-antagonistic activity in a mammal comprising administering to said mammal an effective amount of the compound of any one of claims 1 to 10 together with a pharmaceutically acceptable carrier thereof.